MimiX Biotherapeutics
Bioprinting company using Sound Induced Morphogenesis to create skin tissue for wound healing
- CEO / Founder
- Marc Thurner
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $7.34M
- Latest Round
- Series A
- Key Investors
- Venture Kick, Strategic MedTech investors (Asia/Europe)
Technology & Products
Key Products
Sound Induced Morphogenesis (SIM) bioprocessing for tissue manufacturing, with a lead product called FastSkin, a dermal substitute for acute and chronic wound treatment.
Technological Advantage
Proprietary Sound Induced Morphogenesis technology using sound waves to pattern biological tissues
Differentiation
Value Proposition
FastSkin dermal substitute for acute and chronic wounds using revolutionary acoustic cell patterning
How They Differentiate
Unique acoustic cell patterning technology vs conventional bioprinting
Market & Competition
Target Customers
Wound care clinics, hospitals, burn centers, healthcare providers
Industry Verticals
Healthcare, Wound Care, Regenerative Medicine, Bioprinting
Competitors
Volumina Medical, HCS PHARMA, PeptiMatrix
Growth & Milestones
Growth Metrics
Venture Leaders Medtech 2023 participant; Venture Kick Stage 2 winner (2020); FastSkin approaching US FDA clearance
Major Milestones
Founded 2019, Seed funding, Heraeus strategic investment, FDA clearance pathway initiated
Notable Customers
Scientific and clinical research communities, Partners interested in artificial skin applications, Regenerative medicine researchers, Wound care treatment providers